A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)

Clinical trial NCT06508320 · COMPLETED

Trial details

NCT number: NCT06508320
Sponsor: ModernaTX, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Influenza SARS-CoV-2

Start date: 2024-07-15
Primary completion: 2025-09-25
Enrollment: 932

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.